Dysfunction have recently produced elements for an educational multimedia package for prescribers of the atypical anti-psychotic treatment Seroquel.

Schizophrenia and bipolar disorder are two different mental disorders that affect millions of people across the planet. Seroquel is a psychotropic medication shown to be effective in the treatment of many symptoms of schizophrenia, as well as in the treatment of acute mania associated with bipolar I disorder.

Seroquel (quetiapine) is a novel, atypical antipsychotic medication indicated for the treatment of acute and chronic psychosis including schizophrenia, and for the treatment of acute manic episodes associated with bipolar disorder. Illnesses that affect the brain, such as schizophrenia, may be due to certain chemicals in the brain being out of balance.

Seroquel works by targeting the specific areas of the brain (pre-frontal cortex, striatum, limbic system and anterior pituitary) that are affected by the illness and helps to regulate the actions of the neurotransmitters – dopamine and serotonin – that play an important role in brain functioning.

Seroquel has been licensed for the treatment of schizophrenia since 1997 and for mania associated with bipolar disorder since 2003. Seroquel is available in over 80 countries worldwide, including the US and across Europe.

The 2006/2007 multimedia education package for prescribers of Seroquel features interviews specifically shot and edited by Dysfunction, featuring Professor Gary Sachs of Massachusets General Hospital and Harvard Medical School. The multimedia elements are part of an overall package of educational materials put together by Huntsworth Health-PBC for AstraZeneca Pharmaceuticals